Catheter Precision Q1 2024 revenue $82K, net loss $2.7M; cash drops to $0.5M

Catheter Precision, Inc.

Q1 2024 revenue of $82,000; net loss of $2.7 million.
Cash decreased from $1.5M (Mar 31) to $0.5M (May 6, 2024).
LockeT submitted for CE Mark approval, expected Q3 2024; initial clinical data positive.
Appointed Marie-Claude Jaques as Chief Commercial Officer effective May 1, 2024.
Company is seeking additional financing to pursue business objectives.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Catheter Precision, Inc. reported the quarter ended March 31, 2024 results: revenue $82 thousand, net income ($2.7) million.

Period: the quarter ended March 31, 2024
Revenue: $82 thousand
Net income: ($2.7) million
Result: reported results

Exact text from the filing

were $28 million · Total cash on position at March 31, 2024 was $1.5 million, and $0.5 million at May 6, 2024 · Total revenues for the three months ended March 31, 2024 were $82 thousand · Shareholders’ equity as of March 31, 2024 was $18.5 million · Net loss for the quarter ended March 31, 2024 was ($2.7) million · All revenue as of March 31, 2024 resulted from

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-005695

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.